Mederi Therapeutics to complete new round of financing to advance commercialization of Stretta

Mederi Therapeutics is completing another round of financing in the form of convertible notes.

The proceeds will be used to expand the company's domestic sales force and move forward with the global commercialization of Stretta therapy for gastroesophageal reflux disease.  

Recent data backing the efficacy of Stretta therapy for GERD has also led to expanded insurance coverage.

More articles on gastroenterology:
5 gastroenterologists making the news
11 statistics on gastroenterology & payer relationships
3 ways gastroenterologists can demonstrate value

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast